Xofigo (radium Ra 223 dichloride) is a systemic radiopharmaceutical. Radium is chemically similar to calcium and is taken up by bones in places where bone is actively growing, as in prostate cancer bone metastases. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: combination, radium-223, therapy, Xofigo | Leave a comment »
In December last year we noted an announcement by Bayer that the company was unblinding data from an ongoing clinical trial because of a potential safety issue when radium-223 (Xofigo) was given in combination with abiraterone acetate + prednisone. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, radium-223, safety, Xofigo, Zytiga | Leave a comment »
Bayer is to unblind data early from an ongoing randomized clinical trial of radium-223 acetate — on the guidance of the trial’s Independent Data Monitoring Committee (IDMC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, death, facture, radium-223, risk, safety, trial, Xofigo, Zytiga | Leave a comment »
Radium-223 or Xofigo was first approved in 2013 as “an alpha particle-emitting radioactive therapeutic agent indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.” That meant (and still means) one course of treatment with six cycles of radium-223. However, … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: radium-223, repeat, Treatment, Xofigo | 5 Comments »
According to a joint media release issued earlier today, Bayer HealthCare and Cardinal Health have signed a 15-year agreement for the contract manufacturing of Xofigo® (radium-223 dichloride). … READ …
Filed under: Management, Treatment | Tagged: radium-223, Xofigo | 2 Comments »
According to information on the Malecare Facebook page, Bayer is hoping to be able to re-start manufacturing of radium-223 at their plant in Norway at some time in November. However, no specific date has been provided for product availability, as yet.
Filed under: Uncategorized | Tagged: radium-223, Xofigo | 2 Comments »
On October 21, here in the USA, Bayer HealthCare Pharmaceuticals issued a Dear Healthcare Professional letter to medical professionals indicating that the company still does not know when it is likely to be able to start to re-supply this radiopharmaceutical agent for the treatment of late-stage prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: delay, radium-223, shortage, Xofigo | 3 Comments »
Apparently a problem in the manufacturing process for radium-223 dichoride (Xofigo) at the only plant where the drug is made (in Norway) has required that the plant be temporarily shut down. The supply of radium Ra-223 will run out tomorrow (October 10, 2014) for all current and new patients, worldwide. … READ MORE …
Filed under: Management, Treatment | Tagged: radium-223, Xofigo | 3 Comments »
In a less than entirely surprising move, the UK’s National Institute for Health and Care Excellence has rejected Bayer’s initial application for coverage of radium-223 (Xofigo) under the National Health Service. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: access, NICE, radium-223 | 1 Comment »
According to a report on the MarketWatch web site this morning, Bayer AG’s acquisition of Algeta will be completed before the end of March this year, at which time Bayer will become the sole owner of radium-223 (Xofigo) with full responsibility for the future development and marketing of this drug currently indicated for the treatment of late stage prostate cancer.
Filed under: Drugs in development, Management, Treatment | Tagged: radium-223, Xofigo | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 